

Publisher Correction: Cardiovascular Outcome Trials of Diabetes and Obesity Drugs: Implications for Conditional Approval and Early Phase Clinical Development

Andrew J. Krentz¹ · Gerardo Rodriguez-Araujo¹

Published online: 31 January 2018
© Springer International Publishing AG, part of Springer Nature 2018

Publisher Correction: Pharm Med
<https://doi.org/10.1007/s40290-017-0209-3>

The original version of this article unfortunately contained a mistake. Table 1 was presented incorrectly. The corrected Table 1 is given below.

Table 1 MACE primary composite endpoints applied in diabetes CVOTs to date

Three-point MACE	Four-point MACE
CV death	CV death
Non-fatal myocardial infarction	Non-fatal myocardial infarction
Non-fatal stroke	Non-fatal stroke
	Hospitalization for unstable angina

MACE major adverse cardiovascular events, *CV* cardiovascular, *CVOTs* cardiovascular outcome trials

The original article can be found online at <https://doi.org/10.1007/s40290-017-0209-3>.

✉ Andrew J. Krentz
andrew.krentz@prosciento.com

¹ ProSciento, 855 3rd Avenue Suite 4400, Chula Vista, CA 91911, USA